Additionally, phase I trials are investigating the safety profiles and potential efficacy of new immune checkpoint targets such as T-cell immunoglobulin mucin-3 (TIM-3), T-cell immunoreceptor with immunoglobulin and immune receptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), and lymphocyte activation gene 3 (LAG-3) in treating CRC. This evidence concerns the gene LAG3 and colorectal carcinoma.